Evidence map›Paper›PMID 33104078›Full record

ArticleFrontline gastroenterology2020

Infliximab in acute severe colitis: getting the right dose.

Joseph Fiske, Thomas Conley, Shaji Sebastian, Sreedhar Subramanian

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontline gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Accelerating the Evolution of Immune-Related Enterocolitis Management.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Joseph FiskeDepartment of Gastroenterology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
Thomas ConleyDepartment of Gastroenterology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
Shaji SebastianIBD Unit, Hull University Teaching Hospitals NHS Trust, Hull, UK.ORCID 0000-0002-3670-6545
Sreedhar SubramanianDepartment of Gastroenterology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.ORCID 0000-0002-2162-3528
Royal Liverpool and Broadgreen University Hospital NHS Trust · GBUniversity of Hull · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute severe colitis is a medical emergency and requires prompt treatment with intravenous steroids. Infliximab is typically used as rescue therapy in those who fail to respond to corticosteroids. This article outlines the altered pharmacokinetics of infliximab in acute severe UC and summarised the latest published data surrounding accelerated infliximab dosing.

Indexed as

clinical decision makinginflammatory bowel diseaseinfliximabulcerative colitis

Identifiers

PMID33104078
PMCPMC7569519
OpenAlexW3014874828

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.